Neoadjuvant and perioperative chemoimmunotherapy versus chemotherapy for resectable non-small-cell lung cancer: A systematic review and meta-analysis
Cancer Treatment and Research Communications · 2026 · 49 · 101478
DOI: 10.1016/j.ctarc.2026.101478 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Tianze Zhu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Medical College, Tianjin Medical University, Tianjin, 300270, China. Electronic address: Zhutz0305@163.com. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Although neoadjuvant and perioperative chemoimmunotherapy improve outcomes in resectable non-small-cell lung cancer, treatment effects remain incompletely defined for specific subgroups. We searched PubMed, Embase, and Web of Science through 3 December 2025 and pooled eight randomized trials involving 3387 patients using random-effects models. Exploratory event-free survival (EFS) analyses yielded hazard ratios (HRs) of 0.57 for perioperative and 0.66 for pure neoadjuvant regimens versus chemotherapy. The indirect ratio of HRs was 0.86 (95% CI, 0.63-1.18; interaction P = 0.347), with insufficient precision to establish equivalence. Among patients with PD-L1 tumor-cell expression
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Medical College, Tianjin Medical University, Tianjin, 300270, China. Electronic address: Zhutz0305@163.com.
- Clinical Medical College, Tianjin Medical University, Tianjin, 300270, China. Electronic address: 17379565686@163.com.
- Clinical Medical College, Tianjin Medical University, Tianjin, 300270, China. Electronic address: a17325233643@163.com.
- Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, Chongq…
Zitieren
APA
Zhu, T., Zhou, J., Liu, D., & Li, C. (2026). Neoadjuvant and perioperative chemoimmunotherapy versus chemotherapy for resectable non-small-cell lung cancer: A systematic review and meta-analysis. Cancer Treatment and Research Communications, 49, 101478. https://doi.org/10.1016/j.ctarc.2026.101478
Vancouver
Zhu T, Zhou J, Liu D, Li C. Neoadjuvant and perioperative chemoimmunotherapy versus chemotherapy for resectable non-small-cell lung cancer: A systematic review and meta-analysis. Cancer Treatment and Research Communications. 2026;49:101478. doi:10.1016/j.ctarc.2026.101478
BibTeX
@article{Zhu2026,
author = {Zhu, Tianze and Zhou, Jinxi and Liu, Dewang and Li, Chenhao},
title = {Neoadjuvant and perioperative chemoimmunotherapy versus chemotherapy for resectable non-small-cell lung cancer: A systematic review and meta-analysis},
journal = {Cancer Treatment and Research Communications},
year = {2026},
volume = {49},
pages = {101478},
doi = {10.1016/j.ctarc.2026.101478}
}
EUVIMED